Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.

NYSE · Healthcare · Profile
Abbott Laboratories (ABT) stock profile and business model
What Abbott Laboratories does, how the business earns money, and how valuation, peers, ownership, and risk shape the TECHi profile.
Section freshness
Prices as of Sep 4, 4:04 PM EDT · Fundamentals checked Sep 8, 3:20 AM EDT · Statements Mar 31, 2026
Investor profile snapshot
ABT live price, business model and key metrics
Start with the live market print, then use this profile to connect Abbott Laboratories's operating model with revenue, margins, peer context, and investor risk.
$108.33
▼ -$0.4600(-0.42%)4:04 PM ET - vs previous closeiQuote as of Sep 4, 2026, 4:04 PM EDT
NYSE market is closed. Showing the latest available regular-session trade from Sep 4, 2026, 4:04 PM EDT.
Market data source
Long-term ranges5Y, 10Y, Since first printHide
Live price
$108.33
Live during market hours
Market cap
$187.45B
Equity scale
Analyst view
Buy
Target $120.20 (+10.96% implied)
Company · Profile
About Abbott Laboratories (ABT)
Sector, leadership, and how Abbott Laboratories earns its revenue.
Healthcare
Company · Profile
About Abbott Laboratories (ABT)
Sector, leadership, and how Abbott Laboratories earns its revenue.
Abbott Laboratories
NYSE · ABT · US
- Sector
- Healthcare
- Industry
- Health Care
- Headquarters
- Abbott Park, IL, United States
- Country
- US
- Founded
- 1937
- Employees
- 122,000
- CEO
- Mr. Robert B. Ford
- Exchange
- NYSE
Business identity
Abbott Laboratories company facts and operating footprint
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
- Sector
- Healthcare
- Industry
- Health Care
- Headquarters
- Abbott Park, IL, United States
- Founded
- 1937
- Employees
- 122,000
- CEO
- Mr. Robert B. Ford
- Country
- US
- Exchange
- NYSE
Registration and filing identifiersShowHide
- Asset type
- Common Stock
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
- CIK
- 0000001800
Key metrics
ABT valuation, revenue and margin profile
- Market cap
- $187.45B
- Equity scale
- Revenue TTM
- $45.13B
- Trailing twelve months
- Net margin
- 13.91%
- Profit after expenses
- Revenue growth
- 7.78%
- Latest YoY quarter
- Free cash flow
- $916.00M
- Reported in USD
Margin quality snapshot
Competitors
ABT competitors and peer context
| Ticker | Company | Price | Move |
|---|---|---|---|
| ISRG | Intuitive Surgical | $366.70 | -0.85% |
Risk heatmap
ABT business risks investors should monitor
Valuation sensitivity
Elevated35.06x
Use the forward P/E and PEG context before treating the profile as cheap or expensive.
Balance-sheet flexibility
MonitorD/E 0.65 · CR 1.39
Debt load and near-term liquidity shape how much strategic patience the company has.
Growth durability
Monitor7.78%
Latest YoY revenue growth is the first check on whether the business model is still expanding.
Market sensitivity
MonitorBeta 0.59
Higher beta can amplify drawdowns when rates, earnings expectations, or sector appetite shift.
Regulatory and operating pressure
ElevatedHealthcare
Clinical, reimbursement, approval, and policy shifts can change revenue timing and product economics.
ABT ownership and registration profile
- Float shares
- 1.72B
- Insider ownership
- 0.50%
- Institutional ownership
- 81.91%
- Address
- 100 Abbott Park Road, Abbott Park, IL, 60064-6400, United States
Size & scale
- Market cap
- $187.45B
- Enterprise value
- $214.70B
- Shares outstanding
- 1.74B
- Currency
- USD
Frequently asked
Common questions.
What does Abbott Laboratories do?
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
Where does TECHi source the ABT profile?
ABT profile facts come from company filings and TECHi's market-data providers; any detail that is not available is left blank rather than inferred.
